Tag: Biotech

Posted on

AstraZeneca boosted by good results for biotech asthma drug – Reuters


Reuters

AstraZeneca boosted by good results for biotech asthma drug
Reuters
LONDON AstraZeneca's (AZN.L) drive to rebuild its portfolio of new medicines received a boost on Tuesday with positive results for a biotech drug for severe asthma that the company has previously flagged as a potential $2 billion-a-year product.
AstraZeneca: Asthma drug trial results positiveMarketWatch
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 4 news articles »

View full post on asthma – Google News

Posted on

GSK: New biotech asthma drug – In-Cyprus (press release) (subscription) (blog)


In-Cyprus (press release) (subscription) (blog)

GSK: New biotech asthma drug
In-Cyprus (press release) (subscription) (blog)
GlaxoSmithKline may get a green light from European regulators as early as this week for a new biotech medicine to treat severe asthma, boosting prospects for its struggling respiratory business. A recommendation from the European Medicines Agency …

View full post on asthma – Google News

Posted on

UK Biotech Circassia Moves Into Asthma With Two Acquisitions – Wall Street Journal (blog)


Wall Street Journal (blog)

UK Biotech Circassia Moves Into Asthma With Two Acquisitions
Wall Street Journal (blog)
Allergy and asthma are natural bedfellows: That's the rationale behind Circassia Pharmaceuticals PLC's acquisition spree announced Friday. The Oxford, England, biotech, which is developing vaccines for a range of allergies, has bought Swedish-listed …
UK's Circassia buys two asthma-focused firms for up to $377 millionReuters
Circassia Pharma buys two asthma-focussed companiesReuters UK
Circassia In Share Sale To Fund GBP239 Million In Acquisitions (ALLISS)London South East
Proactive Investors UK –Insider Media –Stock Market Wire
all 9 news articles »

View full post on asthma – Google News

Posted on

Sanofi’s dual-action biotech asthma drug performs well in test – Reuters

Sanofi's dual-action biotech asthma drug performs well in test
Reuters
Nov 11 (Reuters) – An experimental biotech drug for severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting its dual-action mechanism may be highly effective. Dupilumab is a latecomer …
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of …SYS-CON Media (press release)
Regeneron, Sanofi Say Phase 2b trial of Dupilumab Meets Primary EndpointRTT News

all 5 news articles »

View full post on asthma – Google News

Posted on

Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen’s … – Laser Focus world

Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen's …
Laser Focus world
Maxwell Biotech Venture Fund (MBVF), founded with the help of Russian government-backed RVC, announced today that its investment committee approved the terms and the amount of an investment in Eleventa, a Russian biotech company, which was …

View full post on asthma – Google News